CN102905697A - 靶向vegf和/或hif途径、用于治疗中耳炎的化合物如索拉非尼或瓦他拉尼 - Google Patents

靶向vegf和/或hif途径、用于治疗中耳炎的化合物如索拉非尼或瓦他拉尼 Download PDF

Info

Publication number
CN102905697A
CN102905697A CN2011800254426A CN201180025442A CN102905697A CN 102905697 A CN102905697 A CN 102905697A CN 2011800254426 A CN2011800254426 A CN 2011800254426A CN 201180025442 A CN201180025442 A CN 201180025442A CN 102905697 A CN102905697 A CN 102905697A
Authority
CN
China
Prior art keywords
vegf
jbo
mice
otitis media
hif
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800254426A
Other languages
English (en)
Chinese (zh)
Inventor
M.T.奇斯曼
S.D.M.布朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of CN102905697A publication Critical patent/CN102905697A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2011800254426A 2010-03-22 2011-03-18 靶向vegf和/或hif途径、用于治疗中耳炎的化合物如索拉非尼或瓦他拉尼 Pending CN102905697A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1004761.1A GB201004761D0 (en) 2010-03-22 2010-03-22 Method
GB1004761.1 2010-03-22
PCT/GB2011/000382 WO2011117568A1 (en) 2010-03-22 2011-03-18 Compounds targeting the vegf and/or hif pathway such as sorafenib or vatalanib for use in the treatment of otitis media

Publications (1)

Publication Number Publication Date
CN102905697A true CN102905697A (zh) 2013-01-30

Family

ID=42228117

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800254426A Pending CN102905697A (zh) 2010-03-22 2011-03-18 靶向vegf和/或hif途径、用于治疗中耳炎的化合物如索拉非尼或瓦他拉尼

Country Status (8)

Country Link
US (1) US20130078260A1 (https=)
EP (1) EP2549989A1 (https=)
JP (1) JP2013522350A (https=)
CN (1) CN102905697A (https=)
AU (1) AU2011231405A1 (https=)
CA (1) CA2793643A1 (https=)
GB (1) GB201004761D0 (https=)
WO (1) WO2011117568A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106669A (zh) * 2014-11-04 2017-08-29 南加利福尼亚大学 用于治疗过度表达HIF‑1α的癌症的组合物和方法
CN112807293A (zh) * 2021-03-01 2021-05-18 滨州医学院 甲磺酸去铁胺在制备治疗中耳炎药物中的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020006435A (es) * 2017-12-19 2021-02-09 Akouos Inc Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno.
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083458A2 (en) * 2004-12-30 2006-08-10 Bioresponse Llc Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions
US20070249550A1 (en) * 2004-09-01 2007-10-25 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008094208A2 (en) * 2006-08-02 2008-08-07 Northwestern University Protein kinase targeted therapeutics

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070249550A1 (en) * 2004-09-01 2007-10-25 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
WO2006083458A2 (en) * 2004-12-30 2006-08-10 Bioresponse Llc Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JUNG H H ET AL: "Expression of Vascular Endothelial Growth Factor in Otitis Media", 《ACTA OTOLARYNGOL (STOCKH)》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106669A (zh) * 2014-11-04 2017-08-29 南加利福尼亚大学 用于治疗过度表达HIF‑1α的癌症的组合物和方法
CN112807293A (zh) * 2021-03-01 2021-05-18 滨州医学院 甲磺酸去铁胺在制备治疗中耳炎药物中的应用
CN112807293B (zh) * 2021-03-01 2023-06-02 青岛大学 甲磺酸去铁胺在制备治疗中耳炎药物中的应用

Also Published As

Publication number Publication date
EP2549989A1 (en) 2013-01-30
US20130078260A1 (en) 2013-03-28
CA2793643A1 (en) 2011-09-29
WO2011117568A1 (en) 2011-09-29
JP2013522350A (ja) 2013-06-13
AU2011231405A1 (en) 2012-10-04
GB201004761D0 (en) 2010-05-05

Similar Documents

Publication Publication Date Title
Ye et al. Lipopolysaccharide induces neuroinflammation in microglia by activating the MTOR pathway and downregulating Vps34 to inhibit autophagosome formation
Liu et al. Inhibition of autophagy by chloroquine enhances the antitumor efficacy of sorafenib in glioblastoma
Chen et al. Autophagy promotes aortic adventitial fibrosis via the IL-6/Jak1 signaling pathway in Takayasu's arteritis
Shi et al. The RAGE/STAT5/autophagy axis regulates senescence in mesangial cells
US10545134B2 (en) RAC1 inhibitors for the treatment of Alport glomerular disease
Montague-Cardoso et al. Changes in vascular permeability in the spinal cord contribute to chemotherapy-induced neuropathic pain
US20180113139A1 (en) Methods and compositions for diagnosing and treating inflammatory bowel disorders
Ma et al. IL‐33/ST2 axis deficiency exacerbates neutrophil‐dominant allergic airway inflammation
CN105008394A (zh) 治疗结肠直肠癌的方法
Shen et al. AUY922 induces retinal toxicity through attenuating TRPM1
Takamatsu et al. Glomerular angiotensinogen protein is enhanced in pediatric IgA nephropathy
CN102905697A (zh) 靶向vegf和/或hif途径、用于治疗中耳炎的化合物如索拉非尼或瓦他拉尼
Wu et al. VEGFC ameliorates salt-sensitive hypertension and hypertensive nephropathy by inhibiting NLRP3 inflammasome via activating VEGFR3-AMPK dependent autophagy pathway
WO2016081634A1 (en) Compositions and methods for treating endometriosis
Wang et al. PARP16-mediated stabilization of amyloid precursor protein mRNA exacerbates Alzheimer’s disease pathogenesis
Yu et al. Inhibiting SIRT2 attenuates sepsis-induced acute kidney injury via FOXO1 acetylation-mediated autophagy activation
US11357780B2 (en) Methods and compositions relating to the inhibition of IP6K1
Guo et al. Molecular mechanism by which RRM2-inhibitor (cholagogue osalmid) plus bafilomycin A1 cause autophagic cell death in multiple myeloma
Yamauchi et al. Na+-Cl− cotransporter-mediated chloride uptake contributes to hypertension and renal damage in aldosterone-infused rats
Lin et al. ATP6V0A1 protects dopaminergic neurons via the autophagy-lysosomal pathway in Parkinson’s disease
Yang et al. GSDMD deficiency attenuates BPD by suppressing macrophage pyroptosis and promoting M2 polarization
JP2022512706A (ja) 眼科におけるＡｋｔ阻害剤の使用
Sgroi et al. Combined in vivo effect of N-acylethanolamine-hydrolyzing acid amidase and glycogen synthase kinase-3β inhibition to treat multiple sclerosis
Guo et al. CD30 knockout attenuates experimental colitis by reducing inflammatory cytokine production
Wang et al. Thlaspi arvense attenuates colitis-associated colorectal tumorigenesis through suppression of neutrophil recruitment via the NOD/NF-κB pathway

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130130